Karol Turkiewicz

Lubin, DS, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Impact of Coronary Sinus Reducer on Coronary Microcirculation in Refractory Angina.

Impact of Coronary Sinus Reducer on Coronary Microcirculation in Refractory Angina.

Journal: JACC. Cardiovascular interventions

Published: January 12, 2026

Effectiveness of coronary sinus reducer implantation in routine clinical practice: 12-month outcomes.

Effectiveness of coronary sinus reducer implantation in routine clinical practice: 12-month outcomes.

Journal: Polish archives of internal medicine

Published: April 07, 2025

Pre-Procedural Use of Levosimendan in High-Risk ACS-PCI Patients with Reduced Left Ventricle Ejection Fraction-Short-Term Outcomes.

Pre-Procedural Use of Levosimendan in High-Risk ACS-PCI Patients with Reduced Left Ventricle Ejection Fraction-Short-Term Outcomes.

Journal: Journal of clinical medicine

Published: March 19, 2025

Safety and Effectiveness of Coronary Sinus Reducer in the Therapy of Refractory Angina Pectoris-Mid-Term Results of the Real-Life Cohort.

Safety and Effectiveness of Coronary Sinus Reducer in the Therapy of Refractory Angina Pectoris-Mid-Term Results of the Real-Life Cohort.

Journal: Journal of clinical medicine

Published: May 28, 2024

Recovery from severe ischemic cardiomyopathy after high-risk percutaneous coronary intervention facilitated by levosimendan infusion and Impella CP support and prolonged use of a wearable defibrillator vest.

Recovery from severe ischemic cardiomyopathy after high-risk percutaneous coronary intervention facilitated by levosimendan infusion and Impella CP support and prolonged use of a wearable defibrillator vest.

Journal: Postepy w kardiologii interwencyjnej = Advances in interventional cardiology

Published: May 24, 2024

High-risk PCI facilitated by levosimendan infusion and Impella CP support in ACS cohort-pilot study.

High-risk PCI facilitated by levosimendan infusion and Impella CP support in ACS cohort-pilot study.

Journal: Kardiologia polska

Published: May 14, 2024

Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents.

Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents.

Journal: Journal of diabetes research

Published: September 09, 2021

Sex Differences in the Clinical Features and Outcomes of Patients with Acute Coronary Syndrome Treated with Two Generations (Absorb and Magmaris) of Bioresorbable Vascular Scaffolds.

Sex Differences in the Clinical Features and Outcomes of Patients with Acute Coronary Syndrome Treated with Two Generations (Absorb and Magmaris) of Bioresorbable Vascular Scaffolds.

Journal: Journal of clinical medicine

Published: July 20, 2021

Impella protected percutaneous coronary intervention on the last remaining highly calcified coronary artery facilitated by shockwave intravascular lithotripsy and levosimendan infusion.

Impella protected percutaneous coronary intervention on the last remaining highly calcified coronary artery facilitated by shockwave intravascular lithotripsy and levosimendan infusion.

Journal: Kardiologia polska

Published: July 14, 2021

Long-term clinical follow-up of the resorbable magnesium scaffolds in acute coronary syndrome patients.

Long-term clinical follow-up of the resorbable magnesium scaffolds in acute coronary syndrome patients.

Journal: Kardiologia polska

Published: June 14, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026